Ductal carcinoma in situRadiation therapyWomen with ductal carcinoma in situ are treated with breast-conserving surgery and radiation therapy. The impact of an additive boost radiation is under evaluation. All women treated for ductal carcinoma in situ with breast-conserving surgery and whole breast ...
Ductal carcinoma in situ of the breast (DCIS) is rare in younger women, accounting for about 4% of all cases of DCIS in France, and tends to be diagnosed by clinical findings or casually, after plastic surgery. After breast conserving treatment, young age ( less than 40) is a predictive...
In situ ductal carcinomaMicroinvasionHER2Hormone receptorsSentinel lymph nodeRecent improvements in the detection of breast cancer at an early stage have resulted in a rising incidence of breast ductal carcinoma in situ with microinvasion. So far, there is no consensus regarding its optimal management...
ncarcinomam;basal cell —carcinoma basocelular;bronchogenic —carcinoma broncogénico;ductal — in situcarcinoma ductal in situ;hepatocellular—carcinoma hepatocelular;lobular —carcinoma lobulillarorlobular;non-small-cell —carcinoma de células no pequeñas;renal cell —carcinoma de células renales;sma...
Currently, the indication criteria for a SN procedure should be restricted to small tumors (T1) with clinically uninvolved axillary status and patients with ductal carcinoma in situ (DCIS).doi:10.1007/s001040050479P. HohenbergerT. ReuhlJ. Markwardt...
Iconography : Reprise chirurgicale des carcinomes canalaires in situ pour exérèse non in sano : existe-t-il des facteurs de risque ?Ductal carcinoma in situ (DCIS) is a common breast lesion (10% of breast cancers). In most of the cases the standard treatment is a partial ...
situUpstagingCorebiopsyThe diagnosis of ductal carcinoma in situ (DCIS) using core biopsy (CB) does not ensure the absence of invasion on final excision. The risk of invasion and upstaging ranges from 8% to 42.7% in various studies. The role of sentinel lymph node biopsy in patients on ...
The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breastdoi:10.1111/his.13145Parham, David MPinder, Sarah EHistopathology
International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast.doi:10.1016/J.RADONC.2019.07.024Ivo A. OlivottoEmma LinkClaire PhillipsTimothy J. WhelanGuy Bryant...
The biological significance of precancerous lesions and non-invasive carcinoma of the breast are compared, particularly proliferative mastopathy with cellular atypia (so-called mastopathy grade I1I), ductal papillomatosis, non-infiltrating intraductal carcinoma (IDC) and lobular in situ carcinoma (...